ГоловнаArchive of numbers2017Volume 25, issue 3 (92)Dynamics of psychopathological and cognitive impairment in patients with schizophrenia during the course of the treatment
Title of the article Dynamics of psychopathological and cognitive impairment in patients with schizophrenia during the course of the treatment
Authors Panko Tamara
In the section HELP TO PRACTICAL PHYSICIAN
Year 2017 Issue Volume 25, issue 3 (92) Pages 127-132
Type of article Scientific article Index UDK 616.895.8-008.46-008.447:615.851 Index BBK -
Abstract Schizophrenia is a disease with unfavorable dynamics and outcome, with negative social consequences in the form of persistent disturbances of mental activity, destruction of social liaisons, and disability. The aim of the study was to assess the dynamics of conditions of patients with schizophrenia, in general, and cognitive impairment, in particular, in the treatment with Olanzapine (Zolafren). Twenty one patients with a verifi ed diagnosis of schizophrenia were examined including 13 patients with paranoid (F20.0) and 8 with a simple form (F20.6) of schizophrenia. The results of the study suggested that the selected drug had showed a suffi ciently high clinical effi cacy in all patients with schizophrenia. Positive dynamics was confi rmed by a signi fi cant decrease on the PANSS scale sco res: the score on the scale of positi ve symptoms decreased from 18.38 to 12.33 points; the score on the scale of negative symptoms decreased from 23.95 to 15.00 points; indicators of gene ral pathological symptoms decreased from 45.33 to 35.62 points. There was also a signifi - cant increase in personal and social functioning, which was confi rmed by the PSP scores, which signifi cantly increased from 65.24 to 76.00 points. Positive changes were pointed out in the cognitive sphere of patients in the course of therapy. Thus, the patients had a reduction of subjective diffi culties in the informational processing, a fastening of the speed of the informational processing, which was manifested in an increasing of a functional mobility of nervous processes. In addition, the results refl ected an improvement of the attention processes (accuracy and productivity indicators), as well as the speed of the informational processing during the course of the treatment with Zolafren
Key words
Access to full text version of the article pdf download
Bibliography 1. Атлас психи чес кого здоровья, 2014 г. / ВОЗ. 2015. 4 с. 2. Lifetime prevalence and age‐of‐onset distributions of mental disorders in the World Health Organization’s World Mental Health Survey Initiative / R. C. Kessler, M. Angermeyer, J. C. Anthony [et al.] // World Psychiatry. 2007. Vol. 6. Р. 168—176. 3. Отчет ВОЗ: Психи чес кое здоровье: усиление борьбы с психи чес кими рас ст ройствами : информационный бюллетень ВОЗ. № °220. Сентябрь, 2010. 4. NCSR, National Comorbidity Survey Replication, ESEMeD, European Study of the Epidemiology of Mental Disorders, NZMHS, New Zealand Mental Health Survey, MNCS, Mexican National Comorbidity Survey, NSMHWB, Nigerian Survey of Mental Health and Well‐Being // The WHO World Mental Health Surveys: Global Perspectives on the Epidemiology of Mental Disorders / Kessler R. C. и Ustun T. B., Eds. NY : Cambridge University Press, 2008. 5. Марута, Н. О. Стан психічного здоров’я населення та пси- хіатричної допомоги в Україні // НейроNews: психо невро логия и нейропсихиатрия. 2010. № 5 (24). С. 83—90. 6. McEwen, B. S. Mood disorders and allostatic load // Biol Psychiatry. 2003. Vol. 54. P. 200—207. 7. Информационный бюллетень (ВОЗ). Вып. 94, № 4, апрель 2016 г., 241-312. 8. Гуменюк Л. Н., Савин А. А. Первый психоти чес кий эпизод шизо фре нии как медико-социальная проблема // Таври чес кий журнал психиатрии. 2010. Т. 14, № 2 (51). С. 27—34. 9. Марута Н. А., Ярославцев С. А. Шизофрения с комор бид- ными и поведенческими рас ст ройствами (структура комор- бидной патологии критерии диагностики, факторы прогноза и закономерности формирования) // Медична психологія. 2015, № 4. С. 46—50. 10. Стандарты оказания помощи больным шизо фре нией / под. ред. Краснова В. Н., Гуровича И. Я., Мосолова С. Н. [и др.] ; Московский НИИ психиатрии Росздрава. Москва, 2006. Режим доступа : http://www.labclinpharm.ru/35.html). 11. Ягода С. А. Биомаркеры шизо фре нии и пути объективиза- ции психофармакотерапии // Современная терапия психи чес ких рас ст ройств. 2011. № 2. С. 2—7. 12. Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode / Dolores Keating, Stephen McWilliams, Ian Schneider, [et al.] // BMJ Open. 2017; 7: e013881. doi:10.1136/bmjopen-2016-013881 13. Chittaranjan Andrade. Antipsychotic Drugs in Schizophrenia: Relative Effects in Patients with and without Treatment Resistance // J Clin Psychiatry. 77: 12, December. 2016. Р. e1656—1660. 14. Золафрен, інструкція, застосування препарату Золафрен. 15. Kay S., Opler L., Fiszbein A. Positive and Negative Syndrome Scale Manual. North Tonawanda, NY : Multi-Health Systems, 1994. 16. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routing social functioning / Morosini P. L., Magliano L., Brambilla L., [et al.]// Acta Psychiatr Scand. 2000; 101: 323—329. 17. Тест Струпа. Методика словесно-цветовой интерферен- ции. PSYCHOJOURNAL.RU : Научно-популярный психологи чес кий портал. Дата публикации : 9-12-2015, 21:42. 18. Сысоев В. Н. Тест Э. Ландольта. Диагностика работо спо- соб ности. СПб., 2000.